The association between elevated IL-13Rα2 gene expression and adverse clinical outcome suggests that measurement of IL-13Rα2 in ACC patients could be used to differentially diagnose and identify patients at highest risk for a poor prognosis who could benefit from IL-13Rα2 targeted therapy. This evidence concerns the gene IL13RA2 and adrenal cortex carcinoma.